NCT02843204

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is the safety and efficacy of anti-PD-1 plus NK immunotherapy to multiple solid tumors.

Detailed description

By enrolling patients with solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using anti-PD-1 and natural killer (NK) cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Conditions

• Malignant Solid Tumour

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
BIOLOGICAL	NK immunotherapy	Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.

Timeline

• Start date: 2016-07-01
• Primary completion: 2017-07-01
• Completion: 2019-07-01
• First posted: 2016-07-25
• Last updated: 2020-05-28

Locations

1 site across 1 country: China